Bristol Myers' Immunotherapy Combo Shows Durable Survival At Three Years In MPM SettingBenzinga • 09/13/21
According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor TypesBusiness Wire • 09/13/21
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 TrialBusiness Wire • 09/13/21
Bristol Myers Squibb (BMY) Stock Moves -0.71%: What You Should KnowZacks Investment Research • 09/11/21
Bristol Myers Squibb Shares Research Supporting Correlation Between New York Heart Association Functional Class (NYHA class) and Mortality in Obstructive Hypertrophic CardiomyopathyBusiness Wire • 09/11/21
Rose 93 Stock Portfolio August Update, Morning Star Fair Values And Buy Candidate ListSeeking Alpha • 09/09/21
Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021Business Wire • 09/08/21
More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. to Advance Cancer Research in Seventh Annual Coast 2 Coast 4 Cancer RideBusiness Wire • 09/08/21
Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage CancersBusiness Wire • 09/08/21
Bristol Myers Squibb to Take Part in Morgan Stanley 19th Annual Global Healthcare ConferenceBusiness Wire • 09/07/21
Bristol Myers (BMY) Down 1.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 08/27/21
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)Business Wire • 08/23/21